Tumour necrosis factor-α mediates carrageenin-induced knee-joint incapacitation and also triggers overt nociception in previously inflamed rat knee-joints

Pain

Volumn 82, Issue 1, 1999, Pages 81-87

  Tonussi, Carlos R ^a   Ferreira, Sérgio H ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Bradykinin; Carrageenin; Experimental arthritis; Hoe 140; Leukotrienes; MK 886; Tumour necrosis factor

Indexed keywords

3 [3 TERT BUTYLTHIO 1 (4 CHLOROBENZYL) 5 ISOPROPYL 2 INDOLYL] 2,2 DIMETHYLPROPIONIC ACID; BRADYKININ B1 RECEPTOR ANTAGONIST; BRADYKININ B2 RECEPTOR; BRADYKININ B2 RECEPTOR ANTAGONIST; BRADYKININ[8 LEUCINE 9 DEARGININE]; CARRAGEENAN; ICATIBANT; INDOMETACIN; PROSTAGLANDIN E2; SUBSTANCE P; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; INTRAARTICULAR DRUG ADMINISTRATION; KNEE; MALE; NOCICEPTION; NONHUMAN; PHYSICAL DISABILITY; PRIORITY JOURNAL;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARTHRITIS; BRADYKININ; CARRAGEENAN; DINOPROSTONE; INFLAMMATION MEDIATORS; INJECTIONS, INTRA-ARTICULAR; KNEE JOINT; MALE; PAIN; RATS; RATS, WISTAR; RECEPTORS, BRADYKININ; STIMULATION, CHEMICAL; SUBSTANCE P; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0033061315     PISSN: 03043959     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3959(99)00035-4     Document Type: Article

References (37)

1. Amann R., Schuligoi R., Lanz I., Peskar B.A. Effect of a 5-lipoxygenase inhibitor on nerve growth factor-induced thermal hyperalgesia in the rat. Eur. J. Pharmacol. 306:1996;89-91.
2. Beusenberg F.D., Hoogstenden H.C., Bonta I.L., van Amsterdan J.G. Cyclic AMP enhancing drugs modulate eicosanoid release from human alveolar macrophages. Life Sci. 54:1994;1269-1274.
3. Cunha F.Q., Lorenzetti B.B., Poole S., Ferreira S.H. Interleukin-8 as a mediator of sympathetic pain. Br. J. Pharmacol. 104:1991;765-767.
4. Cunha F.Q., Poole S., Lorenzetti B.B., Ferreira S.H. The pivotal role of tumor necrosis factor in the development of inflammatory hyperalgesia. Br. J. Pharmacol. 107:1992;660-664.
5. Davis, A.J. and Perkins, M.N., The involvement of bradykinin B1 and B2 receptor mechanisms in cytokine-induced mechanical hyperalgesia in the rat, Br. J. Pharmacol., 113 (1994a) 63-68.
6. 1 receptors in vivo in a model of persistent inflammatory mechanical hyperalgesia in the rat, Neuropharmacology, 53 (1994b) 127-133.
7. De-Melo, J.D., Tonussi, C.R., D'Orleans-Juste, P. and Rae, G.A., Effects of endothelin-1 on inflammatory incapacitation of the rat knee-joint, J. Cardiovasc. Pharmacol., 31(Suppl. 1) (1998a) S518-S520.
8. De-Melo, J.D., Tonussi, C.R., D'Orleans-Juste, P. and Rae, G.A., Articular nociception induced by endothelin-1, carrageenan and LPS in naive and previously inflammed knee-joints in the rat: inhibition by endothelin receptor antagonists, Pain, 77 (1998b) 261-269.
9. Ferreira S.H., Lorenzetti B.B., Poole S. Bradykinin initiates cytokine-mediated inflammatory hyperalgesia. Br. J. Pharmacol. 110:1993;1227-1231.
10. Ferreira S.H., Cunha F.Q., Lorenzetti B.B., Michelin M.A., Perreti M., Flower R.J., Poole S. Role of lipocortin-1 in the anti-hyperalgesic actions of dexamethasone. Br. J. Pharmacol. 121:1997;883-888.
11. Friedman B.S., Bel E.H., Buntinx A., Tanaka W., Han Y.H., Shingo S., Spector R., Sterk P. Oral leukotriene inhibitor (MK-886) blocks allergen-induced airway responses. Am. Rev. Respir. Dis. 147:1993;839-844.
12. Granfors K., Jalkanen S., Lindberg A.A., Maki-Ikola O., von Essen R., Lahesmaa-Rantala R., Isomaki H., Saario R., Arnold W.J., Toivanen A. Salmonella lipopolysaccharide in synovial cells from patients with reactive arthritis. Lancet. 335:1990;685-688.
13. Griswold D.E., Marshall P., Martin L., Webb E.F., Zabko-Potapovich B. Analgesic activity of SK and F 105809, a dual inhibitor of arachidonic acid metabolism. Agent Actions. 32(Suppl):1991;113-117.
14. Higgs G.A., Follenfant R.L., Garland L.G. Selective inhibition of arachidonate 5-lipoxygenase by novel acetohydroxamic acids: effects on acute inflammatory responses. Br. J. Pharmacol. 94:1988;547-551.
15. Hock F.J., Wirth K., Albus U., Linz W., Gerhards H.J., Wiemer G., Henke S., Breipohl G., Konig W., Knolle J., Schölkens B.A. Hoe-140 a new potent and long acting bradykinin-antagonist: in vitro studies. Br. J. Pharmacol. 102:1991;769-773.
16. Huber M., Beutler B., Keppler D. Role of peptide leukotrienes and their hepatobiliary elimination in endotoxin action. Circ. Shock. 14:1984;233-235.
17. IASP, (International Association For Study of Pain), Ethical guidelines for investigation of experimental pain in conscious animals, Pain, 16 (1983) 109-110.
18. Koch A.E., Kunkel S.L., Strieter R.M. Cytokines in rheumatoid arthritis. J. Invest. Med. 43:1995;28-38.
19. Levine J.D., Lau W., Kwiat G., Goetzl E.J. Leukotriene B4 produces hyperalgesia that is dependent on polymorphonuclear leukocytes. Science. 225:1984;743-745.
20. Lotz, M., Vaughan, J.H. and Carson, D.A. Effects of neuropeptides on production of inflammatory cytokines by human monocytes. Science, 241 (1988) 1218-1221.
21. Matuschak G.M., Mattingly M.E., Tredway T.L., Lechner A.J. Liver-Lung interactions during E. coli endotoxemia (TNFα:leukotriene axis). Am. J. Resp. Crit. Care Med. 149:1994;41-49.
22. Muller-Peddinghaus R., Kohlsdorfer C., Theisen-Popp P., Fruchtmann R., Perzborn E., Beckermann B., Buhner K., Ahr H.J., Mohrs K.H. Bay X1005, a new inhibitor of leukotriene synthesis: in vivo inflammation pharmacology and pharmacokinetics. J. Pharmacol. Exp. Ther. 267:1993;51-57.
23. 8]-BK and Hoe-140, in two models of persistent hyperalgesia in the rat. Pain. 53:1993;191-197.
24. Rackham A., Ford-Hutchinson A.W. Inflammation and pain sensitivity: effects of leukotriene D4, B4 and prostaglandin E1, in the rat paw. Protaglandin. 25:1983;193-203.
25. Regoli D., Barabé J., Park W.K. Receptors for bradykinin in rabbit aortae. Can. J. Physiol. Pharmacol. 55:1977;855-867.
26. Rueff A., Patel I.A., Urban L., Dray A. Regulation of bradykinin sensitivity in peripheral sensory fibres of the neonatal rat by nitric oxide and cyclic GMP. Neuropharmacology. 33:1994;1139-1145.
27. Sartor R.B. Importance of intestinal mucosal immunity and luminal bacterial cell wall polymers in the aetiology of inflammatory joint diseases. Ballieres Clin. Rheumatol. 3:1989;223-245.
28. 4) in human skin. J. Invest. Dermatol. 80:1983;115-119.
29. Souza M.H., Melo-Filho A.A., Rocha M.F., Lyerly D.M., Cunha F.Q., Lima A.A., Ribeiro R.A. The involvement of macrophage-derived tumour necrosis factor and lipoxygenase products on the neutrophil recruitment induced by Clostridium difficile toxin B. Immunology. 91:1997;281-288.
30. Stephenson A.H., Lonigro A.J., Hyers T.M., Webster R.O., Fowler A.A. Increased concentrations of leukotrienes in bronchoalveolar lavage fluid of patients with ARDS or at risk for ARDS. Am. Rev. Respir. Dis. 138:1988;14-19.
31. Thomazzi S.M., Ribeiro R.A., Campos D.I., Cunha F.Q., Ferreira S.H. Tumour necrosis factor, interleukin-1 and interleukin-8 mediate the nociceptive activity of the supernatant of LPS-stimulated macrophages. Mediators Inflamm. 6:1997;195-200.
32. Tonussi C.R., Ferreira S.H. Rat knee-joint carrageenin incapacitation test: an objective screen for central and peripheral analgesics. Pain. 48:1992;421-427.
33. 1 receptor-mediated nociception. Eur. J. Pharmacol. 326:1997;61-65.
34. Ulich T.R., Guo K., Del Castillo J. Endotoxin-induced cytokine gene expression in vivo. I. Expression of tumor necrosis factor mRNA in visceral organs under physiologic conditions and during endotoxemia. Am. J. Pathol. 134:1989;11-14.
35. van Lent P.L., van den Hoek A.E., van den Bersselaar L., van Rooijen N., van den Berg W.B. Role of phagocytic synovial lining cells in experimental arthritis. Agents Actions. 38:1993;C92-C94.
36. Watkins L.R., Wiertelak E.P., Goehler L.E., Smith K.P., Martin D., Maier S.F. Characterization of cytokine-induced hyperalgesia. Brain Res. 654:1994;15-26.
37. Watkins L.R., Goehler L.E., Relton J., Brewer M.T., Maier S.F. Mechanisms of tumor necrosis factor-α (TNF-α) hyperalgesia. Brain Res. 692:1995;244-250.